XYS treatment significantly decreased the CD11b+F4/80+ macrophage population in the primary tumour tissue (XS vs. BS: 4.33 ± 0.15% of live cells vs. 6.40 ± 0.29% of live cells; p= 0.001; XC vs. BC: 2.19 ± 0.21% of live cells vs. 3.23 ± 0.15% of live cells; p= 0.032). The gene discussed is ITGAM; the disease is breast cancer.